Please login to the form below

STING

This page shows the latest STING news and features for those working in and with pharma, biotech and healthcare.

Bayer signs €250m pact with India’s Curadev for STING drugs

started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.

Latest news

AbbVie cures STING fever with Mavupharma acquisition

Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015. ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop small-molecule STING agonists.
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

salve its sting. .
Dynavax is ‘deal-ready’ after solid ESMO data; analyst

STING ‘has not stung’. Merck would be an obvious choice for that role, and the analysts also suggest that a deal for SD-101 could be more likely given a lacklustre ... also that the STING agonists were speculated to be more potent based on biology
A look ahead to key trial readouts at ESMO

Looking at some of the new mechanisms on show, Merck/MSD will also have the first clinical results for its STING activator MK-1454, Adaptimmune will have first-in-human results

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can
Live boulder, live louder

It’s like deconstructing a joke; by the end, the punchline loses its sting.
Medius Deal Watch table for March 2015

825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
Pharma deals in March 2015

One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...